NovavaxNVAX
Recorded

Novavax 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 7 minParticipants14

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, and welcome to the Novavax Third Quarter 2026 Financial Results and Operational Highlights Conference Call. All participants will be in a listen-only mode. Should you need any assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then the number 1 on your telephone keypad. To withdraw your question, simply press star one again. Please note, this event is being recorded. I would now like to turn the conference over to Jim Kelly, Executive Vice President and Chief Financial Officer.

Naina ZamanLead Investor Relations Representative

Please go ahead. Good morning, and thank you for joining us today to discuss our third quarter financial results and operational highlights today on November 5, 2026.

Naina ZamanLead Investor Relations Representative

A press release announcing our results is available on our website at www.novavax.com, and an audio archive of this conference call will be available on our website later today. Before we begin with our prepared remarks, I would like to remind you that this presentation includes forward-looking statements regarding Novavax's current expectations related to, but not limited to, its partnerships, market opportunities, and financial guidance. Our actual results may be materially different from such statements as detailed in the presentation. Discussions of non-GAAP figures and reconciliations to GAAP figures are available in our earnings press release and presentation. Descriptions of the risks and uncertainties associated with Novavax are included in our SEC filings. These can be accessed through our website.

Naina ZamanLead Investor Relations Representative

Joining me today are John Jacobs, our President and CEO, Elaine O'Hara, Chief Strategy Officer, Dr. Bob Walker, Head of R&D, and Jim Kelly, our Chief Financial Officer. I would now like to hand the call over to John.

John JacobsPresident and CEO

Thank you, Naina, and welcome, everyone. As we near the end of 2026, I'm pleased with the progress we have made this year across the three pillars of our strategy: partnering our vaccine technology, driving targeted and capital-efficient R&D innovation, and maintaining a lean and agile operating model. For those new to our story, Novavax is a vaccine technology company focused on creating long-term value through partnerships. We believe our technology can underpin a broad range of vaccines in infectious disease, from viral to bacterial, and we are in the early stages of exploring its potential in oncology. By combining our own innovation with that of our partners and leveraging their manufacturing scale and commercial reach, we aim to expand access to our technology, unlock new opportunities, and build a legacy of lasting impact on global health.

John JacobsPresident and CEO

Our technology platform is the engine behind our business, built on a proven foundation in infectious disease. Today, it is used in two commercial vaccines, Nuvaxovid for COVID-19 and R21/Matrix-M for malaria. Both have demonstrated protection against serious disease and favorable tolerability at population scale, with R21/Matrix-M extending that impact to children as young as five months old in malaria endemic regions. Our technology is also being applied in some of the most attractive vaccine markets. Sanofi recently initiated its phase III influenza COVID-19 combination vaccine trial in Europe. Sanofi management confirmed to us that they are targeting a U.S. phase III start in 2027 to support U.S. approval. The trial in Europe utilizes Novavax's differentiated COVID-19 vaccine and Sanofi's market-leading Fluzone High-Dose influenza vaccine.

John JacobsPresident and CEO

The initiation of the phase III CIC trial triggered a one-time $125 million milestone to Novavax and represents a significant future opportunity. This opens up even greater potential with the global flu and COVID-19 markets having a current combined value that exceeds $10 billion, with significant burden of disease. Beyond viral diseases, we intend to enter the clinic with our differentiated C. diff vaccine candidate as early as next year. With no approved vaccine today, C. diff accounts for roughly half a million cases and over 20,000 in-hospital deaths annually in the U.S. alone. This represents a significant unmet medical need and an opportunity for our technology to help millions of people in what could become a large and significant vaccine market. Vaccine innovation has always been at the core of Novavax.

John JacobsPresident and CEO

We are already an established vaccine technology company, and we plan to expand further in infectious disease with our partners and MTA collaborators while advancing our early work in oncology by bringing in new partners, deepening existing partnerships, and potentially enabling new vaccines. We see significant opportunities for our technology to drive long-term value creation. Now let's take a few moments to touch upon some of the progress we have made over the past few months on the three pillars of our strategy, starting with pillar one, partnering our vaccine technology. As already noted, Novavax earned a $125 million milestone following the initiation of Sanofi's pivotal phase III CIC trial in Europe last month. We are on track to earn an additional $75 million milestone upon the completion of Sanofi's manufacturing technology transfer in mid-2027.

John JacobsPresident and CEO

Sanofi kicked off the 2026/2027 COVID season with Nuvaxovid in the U.S., supported by expanded promotional efforts. They also introduced Nuvaxovid in select international markets, while Takeda continues to successfully promote the vaccine in Japan. We're pleased with the level of collaboration with Pfizer and look forward to continued progress on that front, with the potential to share more about the opportunities ahead as that partnership continues to evolve. Our MTA collaborations continue to advance, with interest from companies and organizations in exploring our technology across a broad range of disease areas. Elaine will elaborate further on our progress within this pillar in a few moments. Now pillar two, targeted and capital-efficient R&D innovation. Our work in R&D at Novavax focuses on three objectives. First, building a library of data to better understand how and where our existing technology can have an impact.

John JacobsPresident and CEO

Second, expanding the utility of our Matrix-M technology platform. Third, advancing select innovative vaccine candidates. We are pleased with our progress in all three of these areas to date, and Bob will elaborate further during his commentary today. Finally, pillar three, lean and agile operating model. Underpinning all of this is our financial discipline. This quarter, we raised our full-year revenue framework and improved our expense guidance, bringing more clarity to our outlook. We continue to drive down costs while maintaining core capabilities that we believe are critical to enable the successful execution of our strategy. Jim will take you through our performance and updated guidance later in the call. In closing, we are building a growing set of opportunities with existing partners, potential new partners, and from our own platform across infectious disease and potentially oncology.

John JacobsPresident and CEO

Over time, it is our vision to see our technology embedded in a diversified set of commercial vaccines and development programs with multiple partners. With that, I will turn the call over to Elaine to provide an update on our partnership efforts.

Elaine O'HaraChief Strategy Officer

Elaine? Thank you, John. I will start with the news we announced last week.

Elaine O'HaraChief Strategy Officer

Sanofi has initiated its phase III influenza COVID-19 combination vaccine trial, earning Novavax a $125 million milestone. The trial, being conducted in Europe, is assessing the safety and immunogenicity of Nuvaxovid in combination with Sanofi's leading flu vaccine, Fluzone High-Dose, also known as Efluelda, in adults age 60 and older. Sanofi has stated that they intend to be one of the first movers in the combination vaccine segment, and we believe this is an important step towards that goal. This milestone reflects how Novavax and Sanofi continue to successfully execute on our agreement, which has to date generated over $1 billion in revenue for Novavax. Sanofi has also confirmed with us their intent to target initiation of a U.S. phase III trial in 2027 to support U.S. approval.

Elaine O'HaraChief Strategy Officer

As a reminder, we are eligible to receive a one-time $225 million milestone on the first commercial sale of a CIC product in the U.S. While Sanofi has communicated preliminary expected timelines, these will be subject to their subsequent updates on clinical activities and, of course, U.S. FDA regulatory pathway. More broadly, we continue to make progress on our partnership with Sanofi. After select market efforts last year, Sanofi has kicked off the 2026/2027 commercial launch of Nuvaxovid with improved awareness efforts in both breadth and depth. The focus is on building awareness of the only non-mRNA COVID vaccine option in the U.S. with its associated favorable tolerability profile.

Elaine O'HaraChief Strategy Officer

Sanofi is bringing their expertise as one of the largest vaccine companies in the world to this market through a seasoned vaccine sales force from one of the world's leading vaccine businesses, availability at major retailers like CVS, Walmart, and Costco, running select pilots across retailers to generate learnings that can help build awareness and uptake over time, kicking off DTC efforts like co-branded advertising on TV and online, creative awareness efforts from Serve Up Protection campaign with USA Pickleball to social content with NBA champion Karl-Anthony Towns from the New York Knicks to drive people into pharmacies, and setting the stage for launches in select ex-U.S. markets in 2026 and beyond. We are pleased with the level of investment that our partner has been making to build awareness and begin to penetrate this market, and with the intent of building meaningful market share over time.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day